Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. Co. is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. Co.'s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. We show 8 historical shares outstanding datapoints in our TRML shares outstanding history coverage, used to compute TRML market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TRML market cap history over the course of time is important for investors
interested in comparing TRML's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TRML versus a peer is one thing; comparing
TRML market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TRML can fluctuate over the course of history.
With this page we aim to empower investors researching TRML by allowing them to research the TRML market cap history. |
Free TRML Email Alerts:
Video: The Importance of Market Cap
